Business

Scienture Holdings, which acquired US rights to Summit Biosciences’s Rezenopy naloxone nasal spray in March 2025, announced that the United States Patent and Trademark Office has granted Summit US Patent No. 12,622,903 B2 covering Rezenopy… Read more . . .

Jiangxi Kvvit Pharmaceutical is paying an undisclosed amount up front, plus potential milestones and royalties, to Merz Therapeutics to acquire the rights to develop and commercialize Merz’s Inbrija levodopa dry powder inhaler in mainland China,… Read more . . .

Australian biotech Rage Bio, which has been developing an inhaled splice-switching oligonucleotide (SSO) for the treatment of COPD, has announced that it has changed its name to Atisama Therapeutics. According to the announcement, the name… Read more . . .

More than a year after the FDA approved Satsuma’s Atzumi (STS 101) intranasal dry powder dihydroergotamine for the treatment of migraine in adults, Satsuma parent company SNBL says that it is still trying to find… Read more . . .

MannKind Corporation announced that it is developing a DPI formulation of MNKD-1501 ralinepag for the treatment of pulmonary arterial hypertension under an agreement with United Therapeutics under a 2018 licensing and collaboration agreement between the companies that… Read more . . .

US-based Transpire Bio announced that it has opened an R&D facility in Shanghai, China with approximately 40 employees who will work on development of generic OINDPs for the UK, European, and Asian Pacific markets. Transpire… Read more . . .

Amneal Pharmaceuticals has announced the launch of a generic beclomethasone MDI and a generic albuterol MDI in the US, noting that these are its first metered dose inhalers in the US market. The company had… Read more . . .

Glenmark Pharmaceuticals announced that it will now directly commercialize and distribute Ryaltris olopatadine / mometasone nasal spray in the US. Hikma acquired US rights to Ryaltris in February 2020 and launched the nasal spray in the… Read more . . .